AbbVie (NYSE: ABBV) announced results from a Phase 2 trial evaluating mirvetuximab soravtansine-gynx (ELAHERE) combined with carboplatin in patients with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA